# Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid Arthritis

> **NCT01244958** · PHASE3 · COMPLETED · sponsor: **Frank Behrens** · enrollment: 156 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Rituximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01244958
- **Lead sponsor:** Frank Behrens
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2016-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01244958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01244958, "Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01244958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*